Can-Fite BioPharma Ltd. (TLV:CANF)
1.000
0.00 (0.00%)
Aug 14, 2025, 2:07 PM IDT
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2024. The number of employees decreased by 3 or -37.50% compared to the previous year.
Employees
5
Change (1Y)
-3
Growth (1Y)
-37.50%
Revenue / Employee
490.98K ILS
Profits / Employee
-5.74M ILS
Market Cap
43.72M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Teva Pharmaceutical Industries | 35,686 |
Danel (Adir Yeoshua) | 4,290 |
Kamada | 420 |
Bait Bakfar | 227 |
SofWave Medical | 126 |
BrainsWay | 120 |
Novolog (Pharm-Up 1966) | 936 |
Ilex Medical | 178 |
Can-Fite BioPharma News
- 15 days ago - Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone - GlobeNewsWire
- 16 days ago - Can-Fite Announces Up To $15.0 Million Public Offering - GlobeNewsWire
- 17 days ago - Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia - GlobeNewsWire
- 21 days ago - Can-Fite BioPharma launches best-efforts offering of ADSs and warrants - Seeking Alpha
- 4 months ago - Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients - GlobeNewsWire
- 4 months ago - Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 4 months ago - Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.67M - Seeking Alpha
- 5 months ago - Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market - GlobeNewsWire